# A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies

> **NCT07572006** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Janssen Research & Development, LLC** · enrollment: 280 (estimated)

## Conditions studied

- Hematologic Neoplasms

## Interventions

- **DRUG:** JNJ-95804306
- **DRUG:** AML SoC
- **DRUG:** CLL/SLL SoC

## Key facts

- **NCT ID:** NCT07572006
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-05-15
- **Primary completion:** 2029-05-18
- **Final completion:** 2032-09-24
- **Target enrollment:** 280 (ESTIMATED)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07572006

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07572006, "A Study of JNJ-95804306 for Relapsed or Refractory Hematological Malignancies". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07572006. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*